Full Press Release Details
Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for
Nutriband is partnering with
Kindeva Drug Delivery to develop Aversa Fentanyl which combines Nutriband's Aversa abuse-deterrent technology with
Kindeva's FDA-approved fentanyl patch.
ORLANDO, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW),
a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed an addendum
to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa Fentanyl, that it has in place with its
partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination
Nutriband and Kindeva have revised their agreement to formalize their
exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments.
Nutriband's AVERSA abuse-deterrent technology can be utilized
to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with
abuse potential including opioids and stimulants.
Nutriband's abuse-deterrent transdermal technology consists of
a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid
and stimulant patch products.
The AVERSA abuse deterrent technology is protected by a broad
international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia,
China, Canada, Mexico, and Australia.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent
opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA
Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.1
About AVERSA Abuse-Deterrent
Transdermal Technology
Nutriband's AVERSA abuse-deterrent transdermal technology incorporates
aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse,
such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered
by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico,